

## Total Synthesis of Optically Active Sordaricin Methyl Ester and its $\Delta^2$ -Derivative†


Nobuo Kato,\*<sup>a</sup> Shigenori Kusakabe,<sup>b</sup> Xue Wu,<sup>a</sup> Masashi Kamitamari<sup>b</sup> and Hitoshi Takeshita\*<sup>a</sup>

<sup>a</sup> Institute of Advanced Material Study, 86, Kyushu University, Kasuga-koen, Kasuga, Fukuoka 816, Japan

<sup>b</sup> Graduate School of Engineering Sciences, 39, Kyushu University, Kasuga-koen, Kasuga, Fukuoka 816, Japan

Optically active sordaricin methyl ester and its  $\Delta^2$ -derivative have been synthesised *via* intramolecular Diels–Alder reaction of appropriate precursors derived from dimeric condensates of iridoid synthons for the first time.


Sordaricin **1** is the aglycon of sordarin, an antibiotic isolated from *Sordaria araneosa*,<sup>1</sup> and its carbon skeleton has been verified as being biosynthesised *via* intramolecular Diels–Alder reaction of two electron-deficient diene and dienophile moieties, generated from congeners, cycloaraneosene **A** and



**A**; X = H  
**B**; X = OH

Fig. 1

† This work was presented at the 36th Symposium of Terpenes, Essential Oils, and Aromatic Compounds, November, 1992, (Nishinomiya, Hyogo), Abstract Paper, pp. 90–92.



Scheme 1




Fig. 2

'hydroxycycloaraneosene' **B**;<sup>2</sup> the total synthesis of **B**,<sup>3</sup> as well as **A**,<sup>4</sup> led to revision of the structure of **B** from that originally proposed.

Construction of the tetracyclic framework of **1** has already been reported by two groups *via* the intramolecular Diels–Alder reaction with simpler derivatives.<sup>5,6</sup>

Based on a retrosynthesis outlined in Scheme 1, we have now completed the first total synthesis of sordaricin methyl ester **1b** and its  $\Delta^2$ -dehydro derivative **2c** *via* an intramolecular Diels–Alder reaction of B-secocycloaraneosane derivatives **3** and **4**, whose first step of preparation was the condensation of two optically active iridoid synthons **5** and **6**.

At first, the stereochemically more simple compound, **2b**, was selected as the target molecule. The starting iridoids, the optically active (3*S*,8*R*)-9-benzyloxy-7-chloroirid-1-ene **5**<sup>7</sup> and (3*S*)-6-methoxy-1-iriden-7-al **6**<sup>‡</sup> were condensed with CrCl<sub>2</sub><sup>8</sup> in dimethylformamide (DMF) to obtain a condensate **7** in 83% yield. Instead of the thermally stable trimethylsilyl (TMS) ether group used in our previous papers, the methyl ether **8** was selected as the protective group for the secondary alcohols for a convenient transformation to the methoxycarbonyl group.

‡ **6** was prepared from (3*S*)-1-iriden-7-al.<sup>6</sup> details of this derivation will be reported in a full paper.


The Cope rearrangement occurred smoothly at 200 °C *via* a 'boat-transition state'<sup>7</sup> to yield a methoxyethene **9**, which was then subjected to singlet-oxygen oxidation;<sup>9</sup> AcCl-promoted rearrangement of the resultant methoxylated allylpropoxy group gave the  $\alpha,\beta$ -unsaturated ester group **10**. The benzyloxy group of **10** was hydrogenolysed with Pd(OH)<sub>2</sub><sup>10</sup> to give alcohol **11** and reprotected with the *tert*-butyldimethylsilyl (TBDMS) group to give **12**. Then, **12** was converted into a dehydro derivative **13** having a cyclopentadiene group by means of MoO<sub>5</sub>-mediated oxidation<sup>11</sup> and successive dehydration. The silyl ether of **13** was then oxidized to give aldehyde **14** *via* deprotection of silyl ether and Swern's oxidation. Its enolate, generated by treatment with Li(TMS)<sub>2</sub>N,<sup>12</sup> was trapped with TMSCl to form a silyloxyethene **15**. The Pd(OAc)<sub>2</sub>-oxidation<sup>7,13</sup> of **15** yielded the desired  $\alpha,\beta$ -unsaturated aldehyde **4**. Spontaneous Diels–Alder reaction of **4** by standing at room temperature for 24 h afforded a tetracyclic compound, **2c**, m.p. 99.5–101 °C, in 66% yield. With this successful Diels–Alder reaction of a model system, we turned our attention to the synthesis of **1**.

For the synthesis of **1**, the tetrasubstituted double bond in the D-ring needs to be reduced after the Cope rearrangement step. However, the previously successful method, an intramolecular proton-transferred metal reduction,<sup>4,14</sup> was not applicable owing to the presence of an  $\alpha,\beta$ -unsaturated ester group in **11**. Thus, hydrogenation of **11** was investigated intensively. Among several catalysts examined, iridium black catalyst<sup>15</sup> gave the dihydro derivative **16** with a good stereoselectivity.<sup>§</sup>

The stereostructure of **16**<sup>¶</sup> was confirmed by <sup>13</sup>C NMR comparisons with reference compounds, **i** [<sup>13</sup>C NMR (CDCl<sub>3</sub>)  $\delta$  37.4 (C-7), 32.5 (C-1), 41.7 (C-2), 47.0 (C-6), 36.8 (C-3) and 15.5 (C-16)], **ii** [<sup>13</sup>C NMR (CDCl<sub>3</sub>)  $\delta$  40.1 (C-7), 43.0 (C-1), 45.9 (C-2), 52.4 (C-6), 41.0 (C-3) and 21.4 (C-16)] and **iii** [<sup>13</sup>C NMR (CDCl<sub>3</sub>)  $\delta$  35.0 (C-7), 26.5 (C-1), 40.2 (C-2), 50.9 (C-6), 39.1 (C-3) and 16.9 (C-16)], prepared during our total

§ With other catalysts, *e.g.* Pd(OH)<sub>2</sub>/C and PtO<sub>2</sub>, 'trans'-reduction to give **16a** occurred to a considerable extent.

¶ The numbering on the carbon framework is based on the biogenetical isoprene rule. Therefore, it is different from that defined in the original paper reporting **1**.<sup>1,2</sup>



**Scheme 2** Reagents and conditions: i,  $\text{CrCl}_3$ -lithium aluminium hydride, DMF; ii, NaH, MeI; iii, xylene, 200 °C; iv,  $^1\text{O}_2$ ; v, AcCl-pyridine (py); vi,  $\text{H}_2$ -Pd(OH) $_2$ ; vii, imidazole, TBDMSCl; viii,  $(\text{TMS})_2\text{NLi}$ ; MoO $_5$ -py complex, hexamethylphosphoramide; ix,  $\text{SOCl}_2$ , py-Ac $_2\text{O}$ ; x,  $\text{Bu}_4\text{NF}$ ; xi,  $(\text{COCl}_2)_2$ -dimethyl sulfoxide, Et $_3\text{N}$ ; xii,  $(\text{TMS})_2\text{NLi}$ , TMSCl; xiii, Pd(OAc) $_2$ ; xiv, benzene, 40 °C; xv, AcOH-H $_2\text{O}$ ; xvi,  $\text{H}_2$ -Ir-Bu'OH, 4 bar

synthesis of **A**.<sup>4</sup> Namely,  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  36.8 (C-7), 32.9 (C-1), 41.2 (C-2), 47.0 (C-6), 36.5 (C-3) and 15.7 (C-16) of **16** are in good accordance with those of **i**. An undesired epimer **16a** [ $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  38.7 (C-7), 42.8 (C-1), 45.6 (C-2), 52.6 (C-6), 40.6 (C-3) and 21.4 (C-16)] was identified to have the same stereochemistry as **ii**.<sup>4</sup>

By means of transformations parallel to those described above, **16** afforded an  $\alpha,\beta$ -unsaturated aldehyde **3** via a cyclopentadiene **17** and a silyloxyethene **18**. The final step, the biomimetic Diels-Alder reaction of **3** to **1c** [ $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  0.77 (3H, d,  $J$  7.0 Hz), 0.87 (3H, d,  $J$  6.5 Hz), 1.03 (3H, d,  $J$  6.5 Hz), 2.24 (1H, br sept,  $J$  7.0 Hz), 2.79 (1H, t,  $J$  4.0 Hz), 3.33 (3H, s), 3.52 (1H, d,  $J$  9.0 Hz), 3.77 (1H, d,  $J$  9.0 Hz), 3.76 (3H, s), 4.54 (1H, d,  $J$  6.5 Hz), 4.55 (1H, d,  $J$  6.5 Hz), 6.07 (1H, dd,  $J$  4.0, 1.5 Hz) and 9.73 (1H, s)];  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  17.4, 21.0, 22.2, 26.4, 27.6, 29.0, 29.4, 31.0, 32.0, 41.4, 41.5, 46.2, 51.8, 55.0, 58.9, 65.4, 72.1, 72.9, 96.7, 130.6, 148.1, 172.7 and 204.3], occurred with a somewhat slower rate than in the case of **4** to **2c** but was completed by heating in benzene at 40 °C for 3 days, in 58% yield (based on **18**). The hydrolysis of **1c** with aqueous AcOH gave **1b** [colourless crystals, m.p. 110–111 °C (lit.<sup>1</sup> m.p. 103 °C)]. Key signals observed in its  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ) spectrum confirmed the identity with the sample derived from natural product, i.e.  $\delta$  0.79 (3H, d,  $J$  7.0 Hz), 0.89 (3H, d,  $J$  6.5 Hz), 1.094 (3H, d,  $J$  6.5 Hz), 2.26 (1H, br sept,  $J$  7.0 Hz), 2.57 (1H, t,  $J$  4.0 Hz), 3.53 (1H, d,  $J$  11.5 Hz), 3.81 (3H, s), 3.91 (1H, d,  $J$  11.5 Hz), 6.09 (1H, dd,  $J$  4.0, 1.5 Hz) and 9.66 (1H, s). Since the biogenesis of **1a** from **B** is established,<sup>2</sup> and the optically active **B** has been synthesised,<sup>3</sup> the present work starting from

common precursors constitutes the synthesis of **1b** with the correct absolute stereochemistry.

Received, 4th January 1993; Com. 3/00004D

## References

- 1 D. Hauser and H. P. Sigg, *Helv. Chim. Acta*, 1971, **54**, 1178; A. Vasella, PhD Dissertation, ETH, Zürich, Switzerland, 1972.
- 2 H. J. Borschberg, PhD Dissertation, ETH, Zurich, Switzerland, 1975.
- 3 N. Kato, X. Wu, S. Tanaka and H. Takeshita, *Chem. Lett.*, 1989, 91; *Bull. Chem. Soc. Jpn.*, 1990, **63**, 1729.
- 4 N. Kato, S. Tanaka and H. Takeshita, *Chem. Lett.*, 1986, 1989; *Bull. Chem. Soc. Jpn.*, 1988, **61**, 3231.
- 5 L. N. Mander and R. P. Robinson, *J. Org. Chem.*, 1991, **56**, 3595.
- 6 N. Kato, X. Wu and H. Takeshita, *Chem. Express*, 1991, **6**, 687.
- 7 N. Kato, K. Nakanishi and H. Takeshita, *Bull. Chem. Soc. Jpn.*, 1986, **59**, 1109.
- 8 Y. Okude, S. Hirao, T. Hiyama and H. Nozaki, *J. Am. Chem. Soc.*, 1977, **99**, 3179.
- 9 H. Takeshita, N. Kato, K. Nakanishi, H. Tagoshi and T. Hatsui, *Chem. Lett.*, 1984, 1495.
- 10 M. D. Pearlman, *Tetrahedron Lett.*, 1967, 1663.
- 11 E. Vedejs, D. A. Engler and J. E. Telschow, *J. Org. Chem.*, 1978, **43**, 188.
- 12 M. W. Rathke, *J. Am. Chem. Soc.*, 1970, **92**, 3222.
- 13 Y. Ito, T. Hirao and T. Saegusa, *J. Org. Chem.*, 1978, **43**, 1101.
- 14 N. Kato, S. Tanaka, H. Kataoka and H. Takeshita, *Chem. Lett.*, 1987, 2295; *J. Chem. Soc., Perkin Trans. 1*, 1989, 1833.
- 15 S. Nishimura, H. Sakamoto and T. Ozawa, *Chem. Lett.*, 1973, 855.